CA-MOVEWORKS
22.2.2024 21:01:33 CET | Business Wire | Press release
Moveworks, the leading AI copilot platform for the enterprise, today announced registration for its annual Moveworks.global conference is now open. The event will take place on April 23, 2024, and will be held both virtually and in-person in San Jose, CA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222535446/en/
In an era where artificial intelligence is not just an advantage but a necessity, Moveworks.global is the must-attend event for industry leaders, developers, and forward-thinkers eager to explore the transformative power of generative AI in business. This event serves as a dynamic platform for participants to engage with the brightest minds in the industry.
With past speakers from world-renowned companies like OpenAI, Salesforce, Honeywell, and more, attendees will learn firsthand how best-in-class organizations are leveraging generative AI to foster unprecedented levels of business agility. From global corporations to smaller enterprises eager to harness the potential of generative AI, Moveworks.global promises to offer invaluable insights for leveraging AI to gain a competitive edge.
Event highlights include:
- Unlocking productivity: Discover the untapped potential of centralizing search and action to streamline operations while enhancing productivity.
- AI adaptability through reasoning: Learn why advanced AI reasoning capabilities are crucial for creating adaptable, intelligent systems that can meet evolving business needs.
- Custom AI solutions: Gain practical knowledge on customizing AI tools to align with specific business processes — accelerating growth and innovation.
- Continuous improvement: Hear success stories and proven strategies from various industries on driving continuous service improvement through AI.
Whether you're aiming to integrate AI into your organization or develop AI-driven solutions, Moveworks.global will open new horizons and inspire actionable strategies for leveraging generative AI within the enterprise.
“Moveworks.global is more than just a conference — it's a catalyst for transformative change with AI,” said Bhavin Shah, CEO and founder of Moveworks. “This year, we're zeroing in on tangible generative AI successes, showcasing actual outcomes and practical frameworks from industry pioneers. It's a unique opportunity to learn from those who've turned their AI visions into reality.”
Join us at Moveworks.global to be at the forefront of the AI revolution in business. Register today to secure your place among leaders pioneering the future of enterprise AI.
For more information and to register, visit: https://global.moveworks.com/2024.
About Moveworks
Moveworks is the leading AI copilot platform for the enterprise. It empowers the workforce to interact with and take action across all business systems through natural language. Powered by the world’s most advanced LLMs and our proprietary MoveLM model, the Moveworks copilot enables users to search information, take action, automate tasks, and generate factually accurate content with generative AI. Companies such as Databricks, Broadcom, Hearst, and Toyota North America leverage Moveworks' out-of-the-box solutions and intuitive developer tools to automate L1 support, enhance the employee experience, and accelerate business transformation.
Founded in 2016, Moveworks has raised $315 million in funding, at a valuation of $2.1 billion. In 2023, it was named to the Forbes Cloud 100 list — a definitive list of the top private cloud companies in the world — and has been included in Forbes’ AI 50 list for five consecutive years.
For more information, visit: Moveworks.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222535446/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
